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Abstract
BACKGROUND—RET fusions are oncogenic drivers in 1 to 2% of non–small-cell lung cancers 
(NSCLCs). In patients with RET fusion–positive NSCLC, the efficacy and safety of selective RET 
inhibition are unknown.
METHODS—We enrolled patients with advanced RET fusion–positive NSCLC who had 
previously received platinum-based chemotherapy and those who were previously untreated 
separately in a phase 1–2 trial of selpercatinib. The primary end point was an objective response (a 
complete or partial response) as determined by an independent review committee. Secondary end 
points included the duration of response, progression-free survival, and safety.
RESULTS—In the first 105 consecutively enrolled patients with RET fusion–positive NSCLC 
who had previously received at least platinum-based chemotherapy, the percentage with an 
objective response was 64% (95% confidence interval [CI], 54 to 73). The median duration of 
response was 17.5 months (95% CI, 12.0 to could not be evaluated), and 63% of the responses 
were ongoing at a median follow-up of 12.1 months. Among 39 previously untreated patients, the 
percentage with an objective response was 85% (95% CI, 70 to 94), and 90% of the responses 
were ongoing at 6 months. Among 11 patients with measurable central nervous system metastasis 
at enrollment, the percentage with an objective intracranial response was 91% (95% CI, 59 to 
100). The most common adverse events of grade 3 or higher were hypertension (in 14% of the 
patients), an increased alanine aminotransferase level (in 12%), an increased aspartate 
aminotransferase level (in 10%), hyponatremia (in 6%), and lymphopenia (in 6%). A total of 12 of 
531 patients (2%) discontinued selpercatinib because of a drug-related adverse event.
CONCLUSIONS—Selpercatinib had durable efficacy, including intracranial activity, with mainly 
low-grade toxic effects in patients with RET fusion–positive NSCLC who had previously received 
platinum-based chemotherapy and those who were previously untreated. (Funded by Loxo 
Oncology and others; LIBRETTO-001 ClinicalTrials.gov number, NCT03157128.)
The RET proto-oncogene encodes a transmembrane receptor tyrosine kinase that is involved 
in normal embryonic development.1 Fusions between sequences that encode the kinase 
domain containing the carboxy terminal region of RET and various upstream gene partners 
lead to abnormal expression and oligomerization of chimeric kinase fusion proteins. These 
fusions result in constitutively active, ligand-independent signaling and oncogenesis.2 
Activating RET fusions typically occur in a mutually exclusive fashion with other cancer 
drivers and lead to classic dependency of the tumor cells on the activated oncogenic kinase.
2–4
RET fusions have been identified in 1 to 2% of patients with non–small-cell lung cancer 
(NSCLC),3,5,6 and they appear to be associated with a high risk of brain metastases.7 
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Multitargeted kinase inhibitors that were initially designed to target other kinases but that 
have some measure of RET inhibition have been evaluated in prospective clinical trials. The 
use of these drugs resulted in only limited clinical benefit,8–11 perhaps because of poor anti-
RET activity, poor pharmacokinetic characteristics, and dose-limiting off-target toxic effects 
that are associated with the concurrent inhibition of multiple non-RET kinases.2,12 These 
toxic effects lead to frequent dose reductions and even permanent drug discontinuation.
Selpercatinib (formerly known as LOXO-292) is a novel, ATP-competitive, highly selective 
small-molecule inhibitor of RET kinase. Experimental models showed that it has nanomolar 
potency against diverse RET alterations, including fusions, activating point mutations, and 
predicted acquired resistance mutations, while mainly sparing non-RET kinases and non-
kinase targets.13 In addition, selpercatinib was designed to penetrate the central nervous 
system (CNS) and has been shown in preclinical models to have antitumor activity in the 
brain. We evaluated the efficacy of selpercatinib in a phase 1–2 clinical trial 
(LIBRETTO-001). Adolescent and adult patients with any type of solid tumor harboring an 
activating RET alteration (i.e., fusions or mutations) were eligible. Here, we report the 
efficacy and safety of selpercatinib in patients with RET fusion–positive NSCLC.
Methods
Patients
Full eligibility criteria for the trial are detailed in the protocol, available with the full text of 
this article at NEJM.org. Eligible patients were 12 years of age or older (in areas where this 
criterion was allowed by regulatory authorities and institutional review boards; otherwise, 
the patients were 18 years of age or older) and had received a diagnosis of advanced or 
metastatic solid tumor. Patients were required to have a prospectively identified RET 
alteration (fusion or mutation) after they had reached dose level 2 (20 mg of selpercatinib 
twice daily), the dose at which steady-state selpercatinib pharmacokinetic exposures were 
predicted to be efficacious as defined by a trough level that exceeded the 50% inhibitory 
concentration for RET kinase activity. RET alteration status was determined by local 
molecular testing performed in a certified laboratory with the use of next-generation 
sequencing, fluorescence in situ hybridization (FISH), or polymerase-chain-reaction (PCR) 
assay. Central confirmation of the locally identified RET alteration was not required.
Other inclusion criteria included an Eastern Cooperative Oncology Group performance-
status score of 0 to 2 (on a scale from 0 to 5, with higher scores indicating greater disability), 
adequate organ function, and a corrected QT interval of 470 msec or less. Any number of 
previous therapies, including immune checkpoint inhibitors, multitargeted kinase inhibitors, 
and chemotherapy, were allowed. Patients with previously treated or untreated brain 
metastases who were either asymptomatic or had been in neurologically stable condition for 
at least 2 weeks were also eligible. Patients had to have a RET fusion–positive NSCLC to be 
included in the current analysis.
This trial was conducted in accordance with the Good Clinical Practice guidelines, the 
principles expressed in the Declaration of Helsinki, and all applicable country and local 
regulations. The protocol was approved by the institutional review board or independent 
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ethics committee at each investigative site. All the patients, or guardians of patients younger 
than 18 years of age, provided written informed consent.
Trial Design and Treatment
This open-label phase 1–2 trial was conducted at 65 centers in 12 countries (Table S1 in the 
Supplementary Appendix, available at NEJM.org). Selpercatinib was administered orally (in 
capsule or liquid formulation), continuously, in 28-day cycles, until disease progression, 
death, unacceptable toxic effects, or withdrawal of consent. Patients who were enrolled in 
the phase 1 dose-escalation portion of the trial received selpercatinib at doses ranging from 
20 mg once daily to 240 mg twice daily. Intrapatient dose escalation to higher doses that 
were determined by the investigators to be safe was permitted after a minimum of one cycle 
of treatment. All patients who were enrolled in the phase 2 portion of the trial received the 
recommended dose of 160 mg twice daily. Patients with documented disease progression 
could continue to receive selpercatinib if, in the opinion of the site investigator, they were 
deriving clinical benefit from this agent.
The primary end point was an objective response (a complete or partial response), as 
determined by an independent review committee of expert radiologists, according to the 
Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1.14 Secondary end 
points included an objective intracranial response, progression-free survival, the duration of 
response, and safety. All responses required confirmation by a second consecutive radiologic 
assessment performed at least 4 weeks after the first assessment showed a response.
Trial Assessments
Radiologic tumor assessments were conducted at baseline, every 8 weeks for 1 year, and 
every 12 weeks thereafter. Brain imaging during screening was mandated for all patients 
who were enrolled in the phase 2 portion of the trial. Patients with brain metastases that 
were identified at baseline underwent repeated brain imaging with each response 
assessment. Adverse events were assessed from the first dose of selpercatinib (or from the 
date that informed consent was obtained in patients with serious adverse events) until the 
safety follow-up visit 28 days after the last dose of selpercatinib was administered. Adverse 
events were graded according to the Common Terminology Criteria for Adverse Events, 
version 4.03.
Trial Oversight
This trial was designed jointly by the sponsor (Loxo Oncology, a wholly owned subsidiary 
of Eli Lilly) and the investigators. The sponsor collected, analyzed, and interpreted the trial 
data in collaboration with the authors. The first draft of the manuscript was written by the 
first author and last author in collaboration with the sponsor. All the authors provided input 
to revise the manuscript. A medical writer paid by the sponsor provided writing assistance. 
All the authors vouch for the completeness and accuracy of the clinical data and analyses 
and for the adherence of the trial to the protocol.
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All the analyses were conducted in accordance with the statistical analysis plan. The primary 
analysis set (Fig. S1), defined with input from the Food and Drug Administration (FDA), 
was based on the first 105 patients who were consecutively enrolled across both the phase 1 
and 2 portions of the trial and who met the following criteria: documented RET fusion–
positive NSCLC as determined by local testing; measurable disease according to RECIST, 
version 1.1; and receipt of one or more lines of chemotherapy, including platinum-based 
chemotherapy, and one or more doses of selpercatinib. By agreement with the FDA, patients 
with nonmeasurable disease who were enrolled in the phase 1 dose-escalation part of the 
trial were also included in the primary analysis. Efficacy was also separately investigated in 
a supplemental analysis set composed of the first 39 consecutively enrolled untreated 
patients with RET fusion–positive NSCLC who otherwise met the above criteria.
Efficacy analyses were performed according to the intention-to-treat principle. The 
incidence of a true objective response of at least 50% in the primary analysis set was 
hypothesized, and we estimated that a sample of 105 patients would provide the trial with 
98% power to establish a lower boundary of 30% for a two-sided 95% exact binomial 
confidence interval. Ruling out a lower limit of 30% for the objective response was 
considered to be clinically meaningful for patients who had tumor that had progressed while 
they were receiving previous platinum-based chemotherapy and who had limited remaining 
treatment options for advancing dis ease. No power calculations were carried out in relation 
to the previously untreated patients. Confidence intervals for responses were calculated with 
the use of the Clopper–Pearson method. The duration of response and progression-free 
survival were estimated with the Kaplan–Meier method. Safety was analyzed in both the 
patients with RET fusion–positive NSCLC who had received platinum-based chemotherapy 
and those who had been previously untreated (as defined above) as well as in the overall 
cohort of 531 patients in the trial who had received selpercatinib by June 17, 2019. The data 
cutoff date was December 16, 2019.
Results
Patients
From May 2017 through December 2018, a total of 105 patients with RET fusion–positive 
advanced NSCLC who had previously received at least platinum-based chemotherapy were 
consecutively enrolled and received treatment across both the phase 1 dose-escalation 
portion of the trial (49 patients) and the phase 1 dose-expansion or phase 2 portion of the 
trial (56 patients). In addition, from December 2017 through June 2019, a total of 39 
previously untreated patients with advanced RET fusion–positive NSCLC were enrolled. 
The demographic characteristics of the patients in both cohorts are summarized in Table 1.
The patients who had previously received platinum-based chemotherapy were heavily pre-
treated. They had received a median of 3 previous systemic therapy regimens (range, 1 to 
15); 55% had received previous anti–programmed cell death protein 1 (PD-1) or anti–
programmed cell death ligand 1 (PD-L1) therapies, and 48% had received previous 
multitargeted kinase inhibitors with anti-RET activity. A total of 36% of the patients had 
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brain metastases at baseline as assessed by the investigators. Baseline characteristics (other 
than previous therapy) were generally similar in the previously treated and previously 
untreated groups, although previously untreated patients tended to have better performance 
status and had a lower incidence of brain metastases at enrollment. A total of 88% of the 
patients who had previously received platinum-based chemotherapy received at least one 
dose of selpercatinib at the recommended phase 2 dose of 160 mg twice daily. All the 
previously untreated patients received 160 mg twice daily.
In patients who had received platinum-based chemotherapy, RET fusions were prospectively 
identified by next-generation sequencing (in tumor in 85 patients and in blood or plasma in 
9), FISH (in 9), or reverse-transcriptase PCR assay (in 2). In total, 62 unique locally 
obtained assays were used to enroll patients across all groups (Table S2).
Efficacy
Among patients who had previously received platinum-based chemotherapy, the percentage 
with an objective response was 64% (95% confidence interval [CI], 54 to 73), as determined 
by the independent review committee (Table 2 and Fig. S2). Two patients (2%) had a 
complete response, 65 (62%) had a partial response, 30 (29%) had stable disease, 4 (4%) 
had progressive disease, and 4 (4%) could not be evaluated (NE). Responses were observed 
regardless of previous therapy with anti–PD-1 or anti–PD-L1 agents (Table S3) or 
multitargeted kinase inhibitors (Table S4). The median duration of response according to the 
independent review committee was 17.5 months (95% CI, 12.0 to NE), and 63% (42 of 67) 
of the responses were ongoing at a median follow-up of 12.1 months (Fig. S3). At 1 year, 
66% (95% CI, 55 to 74) of all the patients were progression-free, and the median 
progression-free survival was 16.5 months (95% CI, 13.7 to NE). Overall, 5 patients (5%) 
were lost to follow-up or withdrew.
According to investigator assessment, the percentage of patients with a response was 70% 
(95% CI, 60 to 78) (Table 2 and Fig. 1). Responses were also observed regardless of the 
specific RET fusion partner (Fig. S4). The median time to response was 1.8 months, 
consistent with the first protocol-mandated assessment (Fig. S5). The median duration of 
response according to investigator assessment was 20.3 months (95% CI, 15.6 to 24.0) (Fig. 
2A). Overall, 58% (42 of 73) of the responses were ongoing at a median follow-up of 14.8 
months, and 71% (52 of 73) of the patients with a response continued to receive treatment 
(treatment was administered beyond RECIST progression in some patients because of 
ongoing clinical benefit). The longest response was ongoing at 26.0 months. The median 
duration of response was similar in the overall group of patients who had previously 
received platinum-based chemotherapy and in the subgroup who had received previous anti–
PD-1 or anti–PD-L1 treatment. At 1 year, 68% of all the patients were progression-free 
according to investigator assessment, and the median progression-free survival was 18.4 
months (95% CI, 16.4 to 24.8) (Table 2 and Fig. 2B).
Among 38 of 105 patients who had previously received platinum-based chemotherapy and 
who had investigator-assessed CNS metastasis at baseline, 11 patients were deemed to have 
measurable lesions according to RECIST, version 1.1, by independent review. Among these 
11 patients, the percentage with an objective intracranial response was 91% (10 of 11 
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patients; 95% CI, 59 to 100) according to independent review, including 3 complete 
responses (in 27%), 7 partial responses (in 64%), and 1 stable disease. The median CNS 
duration of response was 10.1 months (95% CI, 6.7 to NE).
A total of 39 previously untreated patients were evaluated to determine efficacy. Among 
these patients, the percentage with a response was 85% (95% CI, 70 to 94) according to 
independent review and 90% (95% CI, 76 to 97) according to investigator assessment (Table 
2 and Fig. S6). At 6 months, 90% of the responses were ongoing. Neither the median 
duration of response nor the median progression-free survival had been reached at a median 
follow-up of 7.4 and 9.2 months, respectively. None of the patients were lost to follow-up or 
withdrew.
Adverse Events
Table 3 shows adverse events that occurred during treatment, regardless of attribution, as 
well as adverse events that were judged by the investigators to be related to selpercatinib. 
The most common adverse events of grade 3 or 4 were hypertension (in 14% of the 
patients), an increased alanine aminotransferase level (in 13%), an increased aspartate 
aminotransferase level (in 10%), hyponatremia (in 6%), and lymphopenia (in 6%). Six grade 
5 adverse events (in 4% of the patients) were observed; they included sepsis (in 2 patients) 
and cardiac arrest, multiple organ dysfunction syndrome, pneumonia, and respiratory failure 
(in 1 patient each). These events were deemed by the investigators to be unrelated to 
selpercatinib. The adverse-event profile of selpercatinib in the patients evaluated was 
broadly similar to the overall safety profile for all 531 patients who received selpercatinib 
(Table S5). Of all 531 patients who received selpercatinib, dose reduction was warranted in 
160 (30%) because of treatment-related adverse events, and 12 patients (2%) discontinued 
selpercatinib because of treatment-related adverse events, the most common of which were 
an increase in the alanine aminotransferase level (in 2 patients) and drug hypersensitivity (in 
2 patients).
Discussion
It is estimated that RET fusions account for a global lung-cancer burden of more than 10,000 
new cases each year. RET fusions were first identified in lung cancer in 2012.15 At that time, 
only multikinase inhibitors with some degree of preclinical anti-RET activity, such as 
cabozantinib and vandetanib, were available in the clinic. These drugs were repurposed and 
investigated in clinical trials for patients with RET fusion–positive lung cancer. 
Unfortunately, these agents were associated with both limited responses and limited 
response durability, probably because of poor pharmacokinetic features and substantial side 
effects resulting from non–RET kinase inhibition. For example, in a phase 2 trial of 
cabozantinib, the percentage of patients with an objective response was 28% and the median 
progression-free survival was only 6 months, and dose modifications were warranted in 73% 
of the patients.9
The initial clinical testing of selpercatinib in 2017 presented an opportunity to explore the 
efficacy and safety of a selective RET inhibitor in this genetically defined lung-cancer 
subgroup. Selpercatinib had rapid and durable antitumor activity in patients with RET 
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fusion–positive lung cancer, and these outcomes surpassed those previously achieved with 
multikinase inhibitors.9–11,16 These findings established RET fusions as bona fide and 
clinically actionable drivers in lung cancer. Patients had meaningful benefit, even though 
56% had been heavily pretreated with at least three previous systemic therapies and 55% had 
received previous immunotherapy. Nevertheless, 64% of the patients who received 
selpercatinib had an objective response, including durable responses. Among previously 
untreated patients, 85% had a response, and the responses appeared to be durable, although 
the period of follow-up for this subgroup of patients was less than 1 year.
The activity of selpercatinib in our trial was broadly similar to that of targeted therapy in 
patients with NSCLC that harbors other established oncogenic drivers (i.e., EGFR 
mutations,17 and ALK,18 ROS1,19 or NTRK20,21 fusions) for which tyrosine kinase 
inhibitors have been established as first-line therapy.22 Furthermore, the promising 
frequency of intracranial response to selpercatinib is important, given the high estimated 
lifetime risk of brain metastases among patients with RET fusion–positive lung cancer,8 
although the incidence of brain metastases observed in our trial was lower than that in 
previous trials. Selpercatinib was also associated with mainly low-grade toxic effects; this 
finding is consistent with its RET-selective profile and lack of substantial off-target activity. 
Most treatment-related adverse events did not warrant dose interruption or modification. The 
most common grade 3 adverse events were reversible with dose modifications; this finding 
suggests that long-term treatment is feasible, particularly in light of the responses observed 
with selpercatinib at doses as low as 20 mg once daily. Only 2% of the patients discontinued 
selpercatinib because of a drug-related adverse event.
Selpercatinib had substantial antitumor activity in patients with RET fusion–positive lung 
cancers, including those who received selpercatinib as first-line therapy, those who had pre 
viously received at least platinum-based chemotherapy, and those with brain metastases. The 
follow-up of this patient cohort was shorter for patients who received selpercatinib as first-
line therapy than for those who had previously received at least platinum-based 
chemotherapy, but responses continued in the majority of patients more than 1 year after the 
initiation of treatment. Antitumor activity was observed regardless of previous exposure to 
anti–PD-1 or anti–PD-L1 agents or multikinase inhibitors. The continued implementation of 
molecular screening strategies that include the ability to detect RET fusions will be critical 
for identifying patients with NSCLC who may benefit from selpercatinib.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Shown are waterfall plots of the maximum change in tumor size in all target lesions, 
according to investigator assessment (Panel A), in intracranial target lesions in patients who 
had previously received platinum-based chemotherapy, according to independent review 
(Panel B), and in all target lesions in previously untreated patients, according to investigator 
assessment (Panel C). Data for five patients who had previously received platinum-based 
chemotherapy are not shown, since one had nontarget lesions only and four did not undergo 
measurement of the target lesion after the baseline measurement. Data for one patient in the 
untreated group are not shown because the patient discontinued treatment before any 
imaging after baseline was performed. The dashed lines at 20% and −30% indicate growth 
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and shrinkage of target lesions, respectively. Anti–PD-1 denotes anti–programmed cell death 
protein 1 (PD-1), and anti–PD-L1 anti–programmed cell death ligand 1.
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Figure 2. Kaplan–Meier Plots of the Duration of Response and Progression-free Survival.
Shown are data (according to investigator assessment) for patients who had previously 
received platinum-based chemotherapy. Panel A shows the duration of response among 73 
patients with a confirmed response, and Panel B shows progression-free survival among all 
105 patients. Tick marks indicate censored data.
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